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ABSTRACT
Rationale Cannabis use is associated with neuroanatomical alterations in the hippocampus.
While the hippocampus is composed of multiple subregions, their differential vulnerability
to cannabis dependence remains unknown.
Objectives To investigate grey matter alteration in each of the hippocampal subregions
(presubiculum, subiculum, cornu ammonis (CA) subfields CA1-4, and dentate gyrus (DG)) as
associated with cannabis use and dependence.
Methods A total of 35 healthy controls (HC), 22 non-dependent (CB-nondep), and 39
dependent (CB-dep) cannabis users were recruited. We investigated group differences in
hippocampal subregion volumes between HC, CB-nondep, and CB-dep. We further explored
the association between CB use variables (age of onset of regular use, monthly use, lifetime
use) and hippocampal subregions in CB-nondep and CB-dep users separately.
Results The CA1, CA2/3, CA4/DG, as well as total hippocampal grey matter, were reduced in
volume in CB-dep but not in CB-nondep users, relative to HC. The right CA2/3 and CA4/DG
volumes were also negatively associated with lifetime cannabis use in CB-dep users.
Conclusions Our results suggest a regionally- and dependence-specific influence of cannabis
use on the hippocampus. Hippocampal alteration in cannabis users was specific to the CA
and DG regions, and confined to dependent users.

Keywords hippocampus, cannabis, MRI, brain imaging, dependence
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INTRODUCTION
Cannabis is widely used for its psychoactive effects, such as alteration of conscious
perception and sense of time and space, euphoria, and relaxation; ascribed to the impact of
the main psychoactive compound of cannabis, delta9-tetrahydrocannabinol (THC) on the
brain cannabinoid receptor type 1 (CB1R) (Gaoni and Mechoulam 1964; Hall and Degenhardt
2007; Svíženská et al. 2008). A global burden of disease study suggested that in 2010, the
prevalence of cannabis dependence was estimated at 13 million cases (Degenhardt et al.
2013). Cannabis dependence is associated with substantial psychosocial impairment
including interference to productivity, interpersonal relationships difficulties, and poorer
emotional and cognitive functioning (Fergusson and Boden 2008; Volkow et al. 2014), raising
concern for the associated increase in disability in dependent users (Coffey et al. 2002).
A commonly implicated neuroanatomical region that is altered in cannabis users is
the hippocampus (Lorenzetti et al. 2014; Yücel et al. 2016). Preliminary evidence suggests
that volumetric reduction of the hippocampus may be driven by a subgroup of users that are
dependent on cannabis (Lorenzetti et al. 2016). Dependent users experience a loss of control
in their substance use, often using larger amounts or for longer than intended, despite
impairment to their social and occupational functioning (American Psychiatric Association
2013). Progression from controlled substance use to such compulsive use is suggested to be
characterised by distinct neuroplastic changes to critical brain regions including those
involved in reward and conditioned learning, such as the hippocampus (Koob and Volkow
2010; Filbey and Dunlop 2014). However, it is unclear whether this volumetric reduction is
subserved by alteration of specific hippocampal subregions (subiculum, presubiculum, cornu
ammonis (CA) subfields CA1-4, dentate gyrus (DG), and fimbria) (Van Leemput et al. 2009).
This is important because distinct subregions of the hippocampus serve unique functions
ranging from learning and memory (Gabrieli et al. 1997), to the regulation of emotional
behavior and hypothalamic function (Narr et al. 2004). Consequentially, hippocampal
subregions may be differentially affected in disorders involving hippocampal dysfunction, as
demonstrated, for example, in Alzheimer’s Disease, depression, and schizophrenia (Zhao et
al. 2001; Small et al. 2011).

3

Chronic cannabis use is consistently associated with impaired cognitive functioning
along specific domains (attention, verbal learning and memory; rather than working
memory) (Broyd et al. 2016), and poorer mental wellbeing, including elevated stress
(Degenhardt et al. 2003; Hyman and Sinha 2009). Such impairments are directed by the
effect of cannabinoid compounds on the CB1Rs (Svíženská et al. 2008), that are
heterogeneously distributed within hippocampal subregions, with a particularly high
concentration within the molecular layer of the DG, the strata pyramidale of the CA2 and
CA3, and the subiculum (Glass et al. 1997). For example, a rat study demonstrated CB1Rs in
the CA1 region to specifically mediate memory impairment in cannabinoid administration
(Wise et al. 2009). Meanwhile, chronic stress associated with substance use may disrupt
neurogenesis in the DG of the hippocampus (Chambers 2013). Besides region-specific
function impairment, evidence in rat studies also demonstrated cannabinoid-induced
subregion-specific morphological changes (i.e. upregulation of GABA receptor and reduced
dendritic length CA1, dendritic rearrangement in CA3 and lower blade of the DG (Lawston et
al. 2000; Verdurand et al. 2010)). Furthermore, human studies have shown alteration to
hippocampal shape in cannabis users relative to controls (Solowij et al. 2013; Smith et al.
2015), suggesting morphological differences specific to subregions of the hippocampus.
However, no study has yet investigated the relative contributions of various hippocampal
subregions to the hippocampal alterations observed in cannabis users, a strategy that may
provide insight into the mechanism and implications of these neural effects. Similarly, the
extent to which hippocampal subregions may be altered by cannabis use in general, or
cannabis dependence specifically remains unknown.
Here, we examine the volume of hippocampal grey matter subregions (presubiculum,
subiculum, CA1, CA2 and CA3, CA4 and dentate gyrus (DG), and total grey matter (GM)) and
their differential relationships with cannabis use and dependence. We used an automated
segmentation method for hippocampal subregions that allows for the generation and
quantification of subregional volume (Van Leemput et al. 2009) and has been reliably used in
various other studies including major depressive disorders (Han et al. 2016), schizophrenia
and bipolar disorder (Haukvik et al. 2015) to discern regionally specific hippocampal
alterations. We hypothesise that dependent and non-dependent cannabis users (CB-dep and
CB-nondep, respectively) will both demonstrate smaller hippocampal subregion volumes
than healthy controls (HC), with additional subregion alteration specific to CB-dep users.
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METHODS
Participants
A total of 96 participants, including 35 HC, 22 CB-nondep, and 39 CB-dep age- and gendermatched individuals (reported in previous studies; e.g., Zalesky et al. 2012; Yücel et al.
2016)), were recruited via advertisement in local newspapers and internet websites, and
underwent a comprehensive screening to determine eligibility. Inclusion criteria were to be
19 to 55 years of age, right-handed, have an IQ score of >70, to speak English as a first
language, and have normal or corrected-to-normal visual acuity. Cannabis users were to
have used cannabis regularly (at least twice a month) for at least two years, and be willing to
abstain from cannabis use at least 12 hours prior to assessment. Exclusion criteria were any
history of neurological disorders or serious head injury; any personal psychiatric history
requiring treatment; use of psychoactive medications; significant use of substances besides
cannabis, alcohol and tobacco (>50 lifetime occasions); and MRI contraindications. The
depression and psychosis modules of the Structured Clinical Interview for DSM-IV-R (SCID)
were also administered to exclude participants with any depressive or psychotic disorder
(Spitzer et al. 1994; First et al. 2001).

Measures
Participants’ demographic and drug use characteristics, including cannabis, alcohol, and
tobacco use, were assessed through a semi-structured interview, previously employed in
other studies to characterize lifetime and current substance use (Solowij et al. 1995; Yücel et
al. 2010; Solowij et al. 2011; Takagi et al. 2013). Participants’ self-reported substance use
was further corroborated with measure of recent use (Timeline Follow Back, TLFB; Sobell
and Sobell, 1992). A urine toxicology test was used to corroborate self-reported cannabis
use/nonuse in users and HC, and for detection of illicit substance use, with any discrepancies
in reported personal history of use addressed with participants. However, due to the high
variability of urinary THC metabolite levels (depending on factors including time of urine
sampling, body fat content, and degree of urine dilution (Musshoff and Madea 2006; Lowe
et al. 2009)), urinary metabolite levels were not included in our analysis.
CB-nondep and CB-dep users were separated using the Severity of Dependence Scale
(SDS), administered as a self-report questionnaire, with a cut-off score of 4 and above
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indicating cannabis dependence (Gossop et al. 1995). The SDS has good criterion validity
against DSM-IV diagnosis of cannabis dependence (r = .48 – .76), with an optimal
differentiating cut-off of 4 and above (sensitivity = 61.3 – 65.1, specificity = 63.5 – 94.3)
(Martin et al. 2006; Piontek et al. 2008; van der Pol et al. 2013).
Cannabis use was quantified and converted to a standardised unit of ‘cones’, based
on users’ self-report of their amount of use in units familiar to them and use of visual aids
(e.g., grams or joints, with 1 gram = 12 cones, and 1 paper joint = 3 cones;
https://ncpic.org.au/media/1593/timeline-followback.pdf).

The

Alcohol

Use

Disorder

Identification Test (AUDIT) was used to assess level of alcohol use and dependence
(Saunders et al. 1993). IQ was estimated using the Wechsler Abbreviated Scale of
Intelligence (WASI) (Wechsler 1999). Global functioning of participants was assessed using
the Global Assessment of Functioning scale (GAF) (Hall, 1995). Psychological symptoms
(depressive, anxiety and psychotic-like) were assessed with the Beck Depression Inventory
(BDI) (Beck et al. 1961), the State and Trait Anxiety Inventory for trait anxiety (STAI-T)
(Spielberger 2010), and by means of the weighted (for number of questions answered) total
frequency subscale of the Community Assessment of Psychic Experiences (CAPE) (Konings et
al. 2006).

MRI data acquisition and processing
All participants were scanned on a 3T Siemens Trio scanner, using a high-resolution
Magnetization Prepared Rapid Acquisition Gradient Echo (MP-RAGE) sequence (TR =
1,900ms, TE = 2.15ms, field of view = 256mm, voxel size = 0.5 x 0.5 x 1 mm3). All images
underwent noise removal using a pre-filtered rotationally invariant nonlocal means filter
(PRINLM)

(https://sites.google.com/site/pierrickcoupe/softwares/denoising-for-medical-

imaging/mri-denoising) to improve segmentation results (Gaser and Coupé 2010; Eskildsen
and Coupe 2011; Manjón et al. 2012). Subsequently, images were processed using the
FreeSurfer image analysis environment (http://surfer.nmr.mgh.harvard.edu/) version 5.3.0
to obtain hippocampal subregional volume and intracranial volume (ICV). This process
includes motion correction (Reuter et al. 2010), non-uniform intensity (Sled et al. 1998;
Zheng et al. 2009), automated talairach transformation, removal of non-brain tissue
(Ségonne et al. 2004), segmentation of white matter and grey matter volumes (Fischl et al.
2002), and segmentation of the hippocampus and surrounding areas into several subregions
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(i.e., fimbria, presubiculum, subiculum, CA1, CA2/3, and CA4/DG fields, as well as choroid
plexus, hippocampal fissure, and inferior lateral ventricle) (Van Leemput et al. 2009). Total
hippocampal grey matter (GM) was defined as a sum of presubiculum, subiculum, CA1,
CA2/3, and CA4/DG.

Statistical Analysis
Statistical analysis was conducted using IBM SPSS Statistics 22.0. A repeated-measures
analysis of covariance (ANCOVA) was first conducted to assess the difference in hippocampal
subregional volumes between HC, CB-nondep, and CB-dep users, with repeated measures
consisting of volumes in the left and right hemisphere. Gender, intracranial volume (ICV),
age, IQ, global functioning, depressive, anxiety, and psychotic-like symptoms, tobacco and
alcohol use were included as covariates. Further exploration of the association between
cannabis use variables and hippocampal subregional volumes was conducted by regression
analysis in CB-nondep and CB-dep groups separately, with variables including gender, ICV,
IQ, depressive (BDI) and psychotic-like (CAPE weighted frequency) symptoms, monthly
alcohol and tobacco use, age of regular cannabis use, quantity of cannabis used per month,
and estimated lifetime quantity. Depressive and psychotic-like symptoms, as well as alcohol
and tobacco use were selected as predictors for the regression analyses based on previous
evidence of association with hippocampal volume (Small et al. 2011; Durazzo et al. 2013;
Haukvik et al. 2015; Han et al. 2016; Lee et al. 2016).

RESULTS
Demographic and substance use characteristics are presented in Table 1. IQ, GAF, BDI, STAIT, CAPE, and monthly tobacco use were significantly different between HC, CB-nondep, and
CB-dep groups. We explored correlations between these potential confounding variables
and hippocampal subregional volumes in the Supplementary Material 1, to exclude their
influence on CB-dependence effect.

TABLE 1 Demographic and Drug Use Characteristics in Healthy Controls (HC), Non-dependent
Cannabis Users (CB-nondep), and Dependent Cannabis Users (CB-dep), (Mean/n (SD))
HC

CB-nondep a

CB-dep a

N = 35

N = 22

N = 39

F/X2

p

7

Age

30.37 (11.46)

36.27 (11.73)

30.38 (9.99)

2.46

.091

Gender (M / F)

18 / 17

11 / 11

18 / 21

0.22

.90

IQ b

112.71

104.23 (15.16)

99.69 (11.62)

9.41

< .001**

(12.97)
GAF c

86.34 (4.32)

78.27 (9.31)

72.38 (9.08)

29.98

< .001**

BDI c

3.40 (5.12)

4.14 (4.18)

12.92 (10.38)

17.24

< .001**

STAI-T c

33.37 (7.65)

31.91 (12.16)

45.46 (12.52)

15.73

< .001**

CAPE weighted frequency c

1.39 (0.23)

1.48 (0.25)

1.68 (0.30)

11.57

< .001**

20.32 (27.40)

19.39 (26.44)

22.28 (26.73)

0.09

.91

9.43 (4.59)

9.16 (5.46)

11.25 (5.39)

1.65

.20

Smoker status d

9 / 26

20 / 2

38 / 1

52.84

< .001**

Onset regular use (years)

17.18 (3.52)

15.52 (3.87)

15.62 (2.92)

1.09

.34

Cig/mth c

23.03 (79.93)

312.00 (298.86)

250.60 (187.42)

19.53

< .001**

Onset regular use (years)

-

17.23 (3.29)

16.46 (3.44)

0.72

.40

Current use

-

264.32 (246.62)

489.18 (310.20)
8.50

.005*

8.33

.005*

Alcohol
StDr/mth c
AUDIT

c

Tobacco

Cannabis use

(cones/month)
(days/month)

-

21.95 (10.33)

27.46 (4.54)

Lifetime use (cones)

-

71,009.68

80,160.33

(58,857.07)

(86,280.37)

0.20

.66

-

298.94 (410.93)

922.93 (926.20)

2.55

.014*

-

1.50 (0.86)

7.85 (3.26)

79.85

< .001**

THC-COOH (Ng/mg)
Dependence
a

e

a

Dependence measured by Severity of Dependence Scale (SDS); CB-nondep = score of 3 or less, CB-dep = score

of 4 or more (Martin et al. 2006; Piontek et al. 2008; van der Pol et al. 2013).
b

IQ measured by Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler 1999).

c

GAF = Global Assessment of Functioning scale (Hall 1995); BDI = Beck Depression Inventory (Beck et al. 1961);

STAI-T = State and Trait Anxiety Inventory, trait anxiety (Spielberger 2010); CAPE = Community Assessment of
Psychic Experiences (Konings et al. 2006); StDr/mth = number of standard drinks consumed per month; AUDIT
= Alcohol Use Disorders Identification Test (Saunders et al. 1993); Cig/mth = number of cigarettes smoked per
month.
d

Smoker status = number of regular smokers compared to non-smokers, ex-smokers, and occasional smokers.

e

THC-COOH = 11-nor-9-Carboxy-THC, urinary metabolite of delta -tetrahydrocannabinol (THC), quantified in
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nanograms to milligrams.
*P < .05, **P < .001
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Repeated-measures ANCOVA between HC, CB-nondep, and CB-dep users, revealed
that CB-dep, relative to both HC and CB-nondep users, had a smaller CA1 subregion (p = .050
and p = .017, respectively) and significantly smaller CA2/3 (p = .026 and p = .018), CA4/DG (p
= .013 and p = .009) and total hippocampal GM (p = .023 and p = .019) (Table 2 and Figure 1).
No significant differences in hippocampal subregional volumes were found between HC and
CB-nondep users. There were no gender by group interactions, but females across all groups
had smaller volumes in CA2/3 (p = .001) and CA4/DG (p = .015) than males. Tobacco use and
IQ were the only covariates that influenced hippocampal subregional volumes. Monthly
cigarette use significantly affected the presubiculum (F1,79 = 4.78, p = .032) and subiculum
(F1,79 = 6.97, p = .010) volumes, while IQ influenced the subiculum volume only (F1,79 = 4.54, p
= .036).

TABLE 2 Hippocampal Volumes by Subregion in Healthy Controls (HC), Non-dependent Cannabis
Users (CB-nondep), and Dependent Cannabis Users (CB-dep), (mean (SD), mm3)
HC

CB-nondep a

CB-dep a

Group

N = 35

N = 22

N = 39

Difference b

Intracranial cavity (106)

1.51 (0.15)

1.53 (0.14)

1.56 (0.13)

Presubiculum

Left

477.41 (65.37)

459.27 (63.49)

453.23 (53.33)

Right

449.29 (56.88)

436.80 (43.55)

444.67 (56.31)

Left

655.58 (71.26)

656.33 (66.92)

637.35 (68.01)

Right

651.80 (65.79)

643.08 (49.77)

637.07 (65.21)

Left

331.78 (48.62)

331.45 (32.08)

323.40 (42.76)

Right

353.64 (42.13)

347.70 (25.95)

335.26 (41.23)

Left

1,031.38 (107.44)

1,002.18 (116.38)

967.39 (115.92)

Right

1,052.82 (108.93)

1,024.14 (90.17)

981.58 (113.37)

Left

578.81 (52.98)

568.04 (61.33)

541.77 (67.00)

Right

589.78 (57.79)

573.84 (51.25)

551.41 (67.39)

Left

3,424.82 (294.27)

3,374.89 (269.79)

3,268.36 (320.87)

Right

3,454.29 (312.64)

3,386.33 (243.26)

3,312.90 (338.22)

Subiculum

CA1 c

CA2 and CA3 c

CA4 and DG c

Total GM c

a

F2,87

p

0.76

.47

1.60

.21

3.43

.037*

3.74

.028*

4.63

.013*

3.81

.026*

Dependence measured by Severity of Dependence Scale (SDS); CB-nondep = score of 3 or less, CB-dep = score

of 4 or more (Martin et al. 2006; Piontek et al. 2008; van der Pol et al. 2013).
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b

F statistic was adjusted for gender, age, IQ, GAF, BDI, STAI-T, CAPE weighted frequency, tobacco use, alcohol

use, and total intracranial volume as covariates.
c

CA = cornu ammonis; DG = dentate gyrus; Total grey matter (GM) volume = sum of presubiculum, subiculum,

CA1, CA2 and CA3, and CA4 and DG volumes.
*P < .05

Fig. 1 (a) Cross-sectional slices of an MRI scan with corresponding automated segmentation
of hippocampus subfield grey matter; CA = cornu ammonis; DG = dentate gyrus; (b,c,d) CA1,
CA2/3, and CA4/DG volumes (collapsed across left and right hemispheres) in controls (HC),
non-dependent (CB-nondep), and dependent (CB-dep) cannabis users, adjusted for ICV and
gender. Bars represent 95% confidence interval; *p < .05

Further exploration of the association between cannabis use variables and
hippocampal subregional volumes was conducted by regression analysis in CB-nondep and
CB-dep groups separately, with variables including gender, ICV, IQ, depressive (BDI) and
psychotic-like (CAPE) symptoms, alcohol and tobacco use, age of regular cannabis use,
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quantity of cannabis used per month, and estimated lifetime quantity. This revealed that
lifetime quantity of cannabis use predicted right CA2/3 (beta = -.305, t(38) = -2.277, p =
.031), right CA4/DG (beta = -.306, t(38) = -2.316, p = .028), and right total GM (beta = -.255,
t(38) = -2.205, p = .036) volumes. Additionally, IQ predicted left CA2/3 (beta = .337, t(38) =
2.116, p = .043), CA4/DG (beta = .399, t(38) = 2.47, p = .020), and total GM (beta = .324, t(38)
= 2.058, p = .049) volume in CB-dep users, while tobacco use was not a significant predictor
in the models. Meanwhile CB-nondep users showed no significant associations with any
variables.

DISCUSSION
Our study is the first that attempts to dissociate the involvement of distinct hippocampal
subregions in cannabis use and dependence. We found a reduction in hippocampal CA1,
CA2/3, CA4/DG and total hippocampal GM volume confined to CB-dep users relative to both
HC and CB-nondep users. HC and CB-nondep users did not differ significantly in hippocampal
subregional volumes or total GM. This finding is not only consistent with many other studies
in regular cannabis users that have demonstrated hippocampal volume reduction (Lorenzetti
et al. 2014; Yücel et al. 2016), but further suggests that reduced volume is driven by or
confined to particular subregions and to dependent users. This may account for divergent
findings whereby some studies have had less dependent users fail to show reduced
hippocampal volume in cannabis users (Lorenzetti et al. 2014; Weiland et al. 2015;
Mashhoon et al. 2015). Exploratory regression analysis further explicates cannabis effects on
the hippocampus. Reduced right CA2/3 and CA4/DG subregional volumes were associated
with lifetime cannabis dosage in dependent users only.
Dependence in CB users indexes out-of-control use, associated with negative mental
and physical consequences, rather than quantity of use per se (Piontek et al. 2008). We
characterised dependence in our study based on SDS scoring (i.e. with a cut-off of 4 and
above as dependent), on a scale of how ‘out-of-control’ users believe their cannabis use to
be, and whether they exhibit difficulties stopping or worry about going without cannabis
(Gossop et al. 1995). Our CB-dep and CB-nondep groups differed only in monthly cannabis
use, and not in lifetime exposure or age of onset of use. However, current monthly cannabis
use did not predict hippocampal subregional volumes in the multiple regression analysis,
suggesting recent level of use to have a minimal influence on hippocampal volume. Previous
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studies have neglected to consider dependence in examining cannabis-related harms, and as
such this dependence-specific effect has gone unnoticed. In future, identifying users with
dependent symptoms will be important, in both research and clinical settings, to allow for
more targeted intervention. While the SDS is an effective screening instrument against
cannabis dependence (Piontek et al. 2008), it should be considered in adjunct to more
extensive diagnostic and validating criteria in future, to effectively represent cannabisrelated problems in the population.
Our results suggest that cannabis dependence is key in hippocampal subregion
volume alterations. Psychopathology symptom scores and global functioning (GAF, BDI,
STAI-T, CAPE weighted frequency (Beck et al. 1961; Hall 1995; Konings et al. 2006;
Spielberger 2010)) did not influence hippocampal subregional volumes (Supplementary Fig.
1). While IQ was positively associated with left CA2/3 and CA4/DG volumes, suggesting that
both greater dependence and lower IQ are associated with smaller hippocampal subregions,
it was nevertheless accounted for as covariate in the group analyses, suggesting that the link
between cannabis dependence and smaller hippocampal subregions is robust and specific.
The specificity of the involvement of CA2/3 and CA4/DG subregions in cannabis dependence
is furthermore of importance as analysing specific hippocampal subregions may be a useful
means to distinguish the differential involvement of various substances of abuse on
hippocampal morphology. For example, a previous study on hippocampal subregion volume
in chronic cigarette smokers demonstrated that quantity of cigarettes smoked and tobacco
dependence were associated with smaller subiculum and presubiculum (Durazzo et al.
2013). We addressed the influence of tobacco use in our Supplementary Material 1, and only
found a weak positive correlation between subiculum volume and monthly tobacco use. Our
CB-nondep and CB-dep users were additionally matched by level of tobacco use (p = .33),
minimizing its confounding influence on observed dependence-specific CA2/3 and CA4/DG
alterations. This observation agrees with a previous study demonstrating no significant
hippocampal volumetric difference between cannabis users with minimal tobacco use, and
users who used both cannabis and tobacco (Filbey et al. 2015). However, the study
demonstrated an effect of ‘combined cannabis and tobacco’ use on memory performance
(Filbey et al. 2015). As such, despite no observable structural differences, future studies
should still consider the functional consequences of combined cannabis and tobacco use; as
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well as utilise hippocampal subregional analyses as a more fine-grained approach to
distinguishing the dependence-specific effects of substances of abuse on the hippocampus.
Our results highlighted a number of moderators to hippocampal alterations. Firstly,
the association between lifetime cannabis use and reduced CA2/3 and CA4/DG subregional
volumes in the CB-dep group was confined to the right, but not left hemisphere. This may be
due to the distinct gene expression pattern in the right and left hippocampus necessary for
the functional division of memory processes. For example, the right hippocampus is
suggested to be involved in spatial memory, while the left hippocampus is more involved in
episodic memory (Burgess et al. 2002). Furthermore, there is a trend towards a right>left
hippocampal volume in normal adults (Pedraza et al. 2004), which may result in alterations
in the right hippocampus being more apparent. Various other studies have observed
hemisphere-specific alterations associated with cannabis use, whether in the hippocampus
or other brain regions (Yücel et al. 2008; Demirakca et al. 2011; Cousijn et al. 2012; Smith et
al. 2015; Koenders et al. 2016). In sum, the studies highlight the need to consider
aberrations in hemispheric asymmetry as a consequence of cannabis dependence. We also
noticed gender-related differences, in which CA2/3 and CA4/DG were smaller in females as
compared to males. This is unsurprising as sex hormones have been shown to influence
CB1R expression (Riebe et al. 2010), and males and females do exhibit different longitudinal
trajectories of hippocampal volume change during adolescent neurodevelopment (Suzuki et
al. 2005). However, gender differences did not interact with cannabis-dependence-related
alterations, and our HC, CB-dep, and CB-nondep groups were well matched by gender,
suggesting that gender did not confound the observed dependence-specific alterations.
Our finding of smaller hippocampal volumes specific to the subregions CA1, CA2/3
and CA4/DG in CB-dep users is relevant to understanding the functional impairment in
chronic cannabis users. The hippocampal subregions follow a one-way trisynaptic pathway,
from the entorhinal cortex, through to the DG, CA3, CA1, and then the subiculum, with each
region serving a specific function in the information processing path (Amaral and Witter
1989; Gilbert and Brushfield 2009). The hippocampal subregions CA1, CA3 and DG are critical
to support representation, encoding and retrieval of events, allowing the hippocampus to
more efficiently organise information and short-term memory (Kesner 2007). Notably,
memory impairment is one of the most frequently observed problems associated with heavy
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and persistent cannabis use (Broyd et al. 2016), which may be subserved by volume deficits
in CA3 and DG specific to chronic dependent cannabis users.
Additionally, the DG is a major site for adult neurogenesis, which is the ability to
generate new neurons that integrate into hippocampal neural networks by sending axonal
projections to the CA3 (Chambers 2013). This process is implicated in facilitating new
memory formation (Eisch 2002; Kempermann et al. 2004), and is suppressed by exposure to
addictive substances (e.g. opiates, nicotine, and cocaine) (Chambers 2013). As such, altered
DG volume in cannabis-dependent individuals may be mediated by impaired neurogenesis.
However, it is important to note that evidence on the effect of cannabinoids on hippocampal
neurogenesis has been inconsistent, with findings of reduced, increased, or no change in
neurogenesis when cannabinoids are administered in animal studies (Jiang et al. 2005;
Kochman et al. 2006; Alén et al. 2010; Schiavon et al. 2016). This may be due to the variety
of cannabinoids used in these studies, including synthetic (Jiang et al. 2005; Alén et al. 2010)
and non-synthetic (THC (Kochman et al. 2006), and cannabidiol (CBD) (Schiavon et al. 2016))
cannabinoids. Of interest, CBD is suggested to be non-psychogenic, and may be protective
against the effect of THC on the brain and hippocampus (Demirakca et al. 2011; Yücel et al.
2016). Further studies are warranted to test the involvement of neurogenesis in cannabis
dependence, with particular attention to types of cannabinoid compound, and may inform
the development of pro-neurogenic therapies (e.g. exercise (Kandola et al. 2016)) to help
treat cannabis dependence.
There are several potential limitations to our study. Firstly, we are unable to partial
out dependence-specific alterations that are general across substances, versus those that
are specific to cannabis dependence. We did not use the SDS scale to quantify other
substance (i.e. tobacco or alcohol) dependence. Meanwhile, alcohol dependence as assessed
by AUDIT (Saunders et al. 1993) was well-matched across the group. Given that dependencespecific neuroadaptations may span across different substances (Koob and Volkow 2010),
future studies should examine the distinct and interactive effect of various substances in
informing dependence-related neuroalterations. Secondly, we acknowledge the possible
difference in accuracy of FreeSurfer’s automated algorithm in segmenting the different
subfields. Van Leemput et al. (2009) demonstrated good dice similarity coefficient (CA2/3
and subiculum = 0.74; CA4/DG and presubiculum = 0.68; CA1 = 0.62) and correlation (CA2/3,
r = .91, p ≤ .0002; CA4/DG, r = .83, p ≤ .0028; subiculum, r = .60, p ≤ .066; correlation data
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not provided for presubiculum and CA1) between the automated method and gold standard
manual segmentation. Nevertheless, the variation in accuracy when segmenting larger
structures such as CA2/3 and CA4/DG, versus smaller structures such as CA1, may result in
differential sensitivity in detecting changes in these regions. Finally, our study sample was
uneven, with 39 CB-dep users and 22 CB-nondep users. While we did not find an association
between CB use variables and subregional volumes in the CB-nondep users, the much
smaller sample size of the CB-nondep users may have limited our ability to detect a
statistically significant effect. Future studies should attempt to reproduce our dependencerelated effect in larger samples.
To conclude, our study extends on previous findings of neuroanatomical alteration in
the hippocampus in cannabis users to provide a more fine-grained approach to
understanding regional- and dependence-specific interactions. We show that hippocampal
alteration in cannabis users may be specific to the CA and DG regions, and confined to
dependent users. Further studies should explore the functional and behavioral implications
of these subregional effects.
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To verify that the observed CB-dep effect was not confounded by other variables (i.e. IQ,
global functioning, depressive, anxiety, psychosis symptoms, and monthly tobacco use), we
correlated all hippocampal subregional volumes with the aforementioned variables
(Supplementary Fig. 1) in the entire sample (N = 96).
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SUPPLEMENTARY FIG. 1 Scatterplot of correlation between IQ (Wechsler 1999); global functioning (Global
Assessment of Functioning Scale, GAF, Hall 1995); depressive (Beck Depression Inventory, BDI, Beck et al.
1961); anxiety (State and Trait Anxiety Inventory, trait anxiety, STAI-T, Spielberger 2010); psychosis
(Community Assessment of Psychic Experiences, CAPE total weighted frequency, Konings et al. 2006)
symptoms; tobacco use (number of cigarettes smoked per month) against hippocampal subfield volumes,
averaged over left and right hemisphere, corrected for ICV and gender. CA = cornu ammonis; DG = dentate
gyrus: GM = sum of presubiculum, subiculum, CA1, CA2, CA3, CA4 and DG; Cig/mth = cigarettes smoked per
month. * p < .05

IQ was positively associated with the volumes of the subiculum (r = .21, p = .04),
CA2/3 (r = .24, p = .02), and CA4/DG (r = .22, p = .03). However, upon splitting the sample
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into HC, CB-nondep, and CB-dep groups respectively, only the correlation between IQ and
subiculum volume in the HC group (r = .35, p = .04) remains.
GAF, BDI, STAI-T, and CAPE scores were not correlated with any hippocampal
subregional volumes (range of r = -.17 – .18, p ≥ .09).
Tobacco use (cigarettes per month) was positively correlated with subiculum volume
(r = .20, p = .05) in the entire sample. However when the sample was split into HC, CBnondep, and CB-dep groups, only the association in the HC (r = .40, p = .02) and CB-nondep
users (r = .48, p = .03) remain.

Tobacco Use

To further verify that the observed CB-dep effect was not confounded by concurrent
tobacco use, we split the CB-nondep and CB-dep users into high and low tobacco use groups
respectively, using a cut-off of 200 cigarettes per month (i.e. median monthly cigarette use,
see Supplementary Table 1 for group demographics). Repeated-measures ANCOVA, with
covariates including gender, ICV, and IQ, determined no effect of tobacco use groups on
hippocampal subregional volumes (Supplementary Table 2).
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SUPPLEMENTARY TABLE 1 Demographic and Drug Use Characteristics in Non-dependent Cannabis Users with High and Low Tobacco Use (CB-nondeplowTOB and CB-nondep-highTOB Respectively), and Dependent Cannabis Users with High and Low Tobacco Use (CB-dep-lowTOB and CB-dep-highTOB
Respectively), (Mean/n (SD))
CB-nondep-lowTOB a,b

CB-nondep-highTOB

CB-dep-lowTOB

CB-dep-highTOB

F/X2

p

N = 10

N = 12

N = 20

N = 19

Age

32.30 (11.83)

39.58 (11.03)

28.25 (9.34)

32.63 (10.41)

2.95

.040*

Gender (M / F)

6/4

5/7

9 / 11

9 / 10

0.84

0.84

111.80 (8.36)

97.92 (16.90)

100.16 (13.22)

101.33 (13.07)

2.88

.044*

GAF d

82.50 (5.32)

74.75 (10.60)

72.60 (10.54)

72.16 (7.54)

3.36

.025*

BDI d

2.10 (1.45)

5.83 (4.97)

15.90 (11.18)

9.79 (8.67)

7.21

< .001**

STAI-T d

29.30 (14.75)

34.08 (9.64)

49.80 (12.30)

40.89 (11.33)

8.10

< .001**

CAPE weighted frequency d

1.43 (0.18)

1.52 (0.30)

1.78 (0.29)

1.58 (0.28)

4.32

.008*

29.09 (33.36)

12.11 (18.09)

22.82 (27.50)

21.72 (26.63)

0.76

.52

10.67 (5.03)

7.89 (5.68)

10.45 (4.66)

12.09 (6.09)

1.49

.23

Onset regular use (years)

17.67 (3.74)

13.92 (3.23)

16.35 (2.64)

14.84 (3.06)

3.34

.025*

Cig/mth d

58.50 (57.10)

523.25 (246.47)

103.65 (64.04)

405.28 (143.45)

35.11

< .001**

Onset regular use (years)

19.40 (3.44)

15.42 (1.78)

16.45 (3.14)

16.47 (3.82)

3.05

.036*

Current use (cones/month)

121.20 (119.81)

383.58 (265.02)

485.65 (265.65)

492.89 (358.65)

4.53

.006*

15.50 (10.31)

27.33 (6.87)

27.50 (4.37)

27.42 (4.83)

10.01

< .001**

IQ

c

Alcohol
StDr/mth d
AUDIT

d

Tobacco

Cannabis use

(days/month)
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Lifetime use (cones)

40,546.80 (46,404.49)

96,395.42 (57,488.14)

58,749.80 (58,266.43)

102,697.74 (105,293.23) 2.20

.098

Dependence a

1.20 (0.92)

1.75 (0.75)

7.90 (3.66)

7.79 (2.88)

< .001**

25.90

a

Dependence measured by Severity of Dependence Scale (SDS); CB-nondep = score of 3 or less, CB-dep = score of 4 or more (Martin et al. 2006; Piontek et al. 2008; van der Pol et al. 2013).

b

lowTOB = low tobacco use = 200 or less cigarettes per month, highTOB = high tobacco use = greater than 200 cigarettes per month.

c

IQ measured by Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler 1999).

d

GAF = Global Assessment of Functioning scale (Hall 1995); BDI = Beck Depression Inventory (Beck et al. 1961); STAI-T = State and Trait Anxiety Inventory, trait anxiety (Spielberger 2010);

CAPE = Community Assessment of Psychic Experiences (Konings et al. 2006); StDr/mth = number of standard drinks consumed per month; AUDIT = Alcohol Use Disorders Identification Test
(Saunders et al. 1993); Cig/mth = number of cigarettes smoked per month.
*P < .05, **P < .001
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SUPPLEMENTARY TABLE 2 Hippocampal Subregional Volumes in Non-dependent Cannabis Users with High and Low Tobacco Use (CB-nondep-lowTOB and
CB-nondep-highTOB Respectively), and Dependent Cannabis Users with High and Low Tobacco Use (CB-dep-lowTOB and CB-dep-highTOB Respectively),
(mean (SD), mm3)
CB-nondep-lowTOB a,b

CB-nondep-highTOB

CB-dep-lowTOB

CB-dep-highTOB

TOB c

N = 10

N = 12

N = 20

N = 19

F1,51

p

F1,51

p

Intracranial cavity (10 )

1.54 (0.17)

1.47 (0.11)

1.56 (0.14)

1.55 (0.13)

Presubiculum

Left

450.11 (75.34)

466.91 (53.96)

452.32 (53.49)

453.78 (53.18)

Right

428.23 (53.52)

443.94 (33.99)

451.68 (58.01)

437.67 (53.45)

1.57

.22

2.59

.11

Left

653.35 (60.56)

658.80 (74.40)

641.13 (66.78)

633.42 (69.12)

Right

637.43 (59.98)

647.79 (41.63)

635.73 (55.49)

638.71 (74.51)

1.87

.18

1.86

.18

Left

339.64 (30.78)

324.62 (50.18)

322.16 (35.07)

323.64 (50.18)

Right

345.75 (28.15)

349.32 (25.11)

336.48 (39.94)

333.92 (42.59)

0.10

.75

0.01

.93

Left

1,035.94 (132.71)

974.04 (97.70)

961.87 (81.76)

967.50 (147.06)

Right

1,031.51 (116.38)

1,018.01 (65.95)

979.96 (86.79)

976.64 (140.17)

0.01

.95

0.05

.83

Left

582.69 (70.46)

555.84 (52.55)

541.05 (56.22)

540.84 (77.73)

Right

576.34 (64.80)

571.76 (39.61)

552.12 (51.84)

546.78 (82.92)

0.00

.97

0.03

.86

Left

3,104.07 (1,065.49)

3,341.15 (270.70)

3,262.27 (284.56)

3,260.87 (362.42)

Right

3,058.92 (1,061.07)

3,403.52 (173.07)

3,309.76 (275.99)

3,303.38 (400.17)

2.96

.09

2.60

.11

6

Subiculum

CA1 d

CA2 and CA3 d

CA4 and DG d

Total GM d

DEP x TOB c

a

Dependence measured by Severity of Dependence Scale (SDS); CB-nondep = score of 3 or less, CB-dep = score of 4 or more (Martin et al. 2006; Piontek et al. 2008; van der Pol et al. 2013).

b

lowTOB = low tobacco use = 200 or less cigarettes per month, highTOB = high tobacco use = greater than 200 cigarettes per month.

c

F statistic was adjusted for gender, IQ, and total intracranial volume as covariates; TOB = fixed effect of tobacco use, DEP x TOB = interaction effect of dependence and tobacco use.

d

CA = cornu ammonis; DG = dentate gyrus; Total grey matter (GM) volume = sum of presubiculum, subiculum, CA1, CA2 and CA3, and CA4 and DG volumes.
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